Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Atsuko Ogino, Ph.D., M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Kosaka T, Tanizaki J, Paranal RM, Endoh H, Lydon C, Capelletti M, Repellin CE, Choi J, Ogino A, Calles A, Ercan D, Redig AJ, Bahcall M, Oxnard GR, Eck MJ, Jänne PA. Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Res. 2017 05 15; 77(10):2712-2721. PMID: 28363995.
    View in: PubMed
  2. Tricker EM, Xu C, Uddin S, Capelletti M, Ercan D, Ogino A, Pratilas CA, Rosen N, Gray NS, Wong KK, Jänne PA. Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer. Cancer Discov. 2015 Sep; 5(9):960-971. PMID: 26036643; PMCID: PMC4824006.
  3. Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Jänne PA. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013 Aug 15; 19(16):4532-40. PMID: 23833300.
    View in: PubMed
  4. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, Capelletti M, Shimamura T, Ercan D, Stumpfova M, Xiao Y, Weremowicz S, Butaney M, Heon S, Wilner K, Christensen JG, Eck MJ, Wong KK, Lindeman N, Gray NS, Rodig SJ, Jänne PA. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011 Sep 15; 71(18):6051-60. PMID: 21791641.
    View in: PubMed
  5. Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, Otani H, Kubo T, Jida M, Ueno T, Ando M, Ogino A, Kiura K, Miyoshi S. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer. 2012 Feb; 75(2):161-6. PMID: 21767894.
    View in: PubMed
  6. Sawada S, Yamashita M, Komori E, Suehiro H, Ogino A, Nogami H, Segawa Y, Shinkai T. [Current status of adjuvant chemotherapy for resected lung cancer at our institute--focus on clinical trial enrollment]. Gan To Kagaku Ryoho. 2010 Mar; 37(3):439-42. PMID: 20332679.
    View in: PubMed
  7. Ichihara E, Ohashi K, Takigawa N, Osawa M, Ogino A, Tanimoto M, Kiura K. Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. Cancer Res. 2009 Jun 15; 69(12):5091-8. PMID: 19491268.
    View in: PubMed
  8. Segawa Y, Takata S, Fujii M, Oze I, Fujiwara Y, Kato Y, Ogino A, Komori E, Sawada S, Yamashita M, Nishimura R, Teramoto N, Takashima S. Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications. J Cancer Res Clin Oncol. 2009 Aug; 135(8):1055-9. PMID: 19152002.
    View in: PubMed
  9. Ogino A, Shinkai T. [Intrapleural chemotherapy--current status and problems in Japan]. Gan To Kagaku Ryoho. 2008 Jun; 35(6):896-9. PMID: 18633216.
    View in: PubMed
  10. Ogino A, Kitao H, Hirano S, Uchida A, Ishiai M, Kozuki T, Takigawa N, Takata M, Kiura K, Tanimoto M. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res. 2007 Aug 15; 67(16):7807-14. PMID: 17699786.
    View in: PubMed
  11. Toyooka S, Uchida A, Shigematsu H, Soh J, Ogino A, Takata M, Kiura K, Ouchida M, Kosaka T, Aoe M, Mitsudomi T, Date H. The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants. J Thorac Oncol. 2007 Apr; 2(4):321-4. PMID: 17409805.
    View in: PubMed
  12. Uchida A, Hirano S, Kitao H, Ogino A, Rai K, Toyooka S, Takigawa N, Tabata M, Takata M, Kiura K, Tanimoto M. Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Sci. 2007 Mar; 98(3):357-63. PMID: 17270025.
    View in: PubMed
  13. Matsuo K, Kiura K, Tabata M, Uchida A, Hotta K, Niiya D, Kubonishi S, Ogino A, Fujiwara Y, Nakajima H, Shinagawa K, Ishimaru F, Ueoka H, Tanimoto M. Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution. Am J Hematol. 2006 May; 81(5):349-54. PMID: 16628731.
    View in: PubMed
  14. Hotta K, Takigawa N, Kiura K, Tabata M, Umemura S, Ogino A, Uchida A, Bessho A, Segawa Y, Shinkai T, Nogami N, Harita S, Okimoto N, Ueoka H, Tanimoto M. Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer. Anticancer Res. 2005 May-Jun; 25(3c):2429-34. PMID: 16080470.
    View in: PubMed
  15. Hotta K, Ueoka H, Kiura K, Tabata M, Ogino A, Umemura S, Harita S, Gemba K, Yonei T, Bessho A, Maeda T, Tanimoto M. Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Acta Oncol. 2005; 44(7):717-22. PMID: 16227162.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Ogino's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (108)
Explore
_
Co-Authors (17)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.